Year: 2025

European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency

LONDON, UK and REYKJAVIK, ICELAND (OCTOBER 6, 2025) — Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company...

Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy

Successful meeting with FDA enables advancement into pivotal development with Privosegtor in Acute Optic Neuritis (AON) and Non-arteritic Anterior Ischemic...

Cannabis Bioscience International Holdings, Inc. Appoints Veteran Financier Andy Trivedi to Its Board of Directors, Strengthening Capital Strategy and Growth Outlook

Houston, Texas--(Newsfile Corp. - October 6, 2025) - Cannabis Bioscience International Holdings, Inc., (OTCID: CBIH), a publicly traded biomedical cannabis...

Pentixapharm Highlights Expanding CXCR4 Radiopharmaceutical Platform with New Clinical Findings at EANM 2025

Clinical data from independent investigator-initiated studies using Ga-PentixaFor demonstrate potential to improve diagnosis in Primary AldosteronismFirst-in-human findings with Lu-PentixaTher in...

error: Content is protected !!